Prifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara's Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD

In a 607-participant Phase 3 psoriasis trial, once-daily prifemilast 20 mg achieved Week 16 PASI 75 in 64.6% of patients versus 35.3% with apremilast 30 mg twice daily, and clear or almost clear skin in 55.6% versus 31.3% (both co-primary endpoints, P<0.0001). Serious adverse events and adverse-event discontinuations were low and similar between treatment arms; a separate placebo-controlled Phase 3 trial reported responses maintained through 52 weeks. cAMPfield plans global Phase 2 trials in ulcerative colitis and Crohn’s disease; prifemilast remains investigational and is not approved, while partner Newsoara plans to submit a psoriasis NDA in China by the end of 2026.

Analysis

The read-through for Amgen is a long-dated competitive risk to Otezla, not a near-term earnings event. A differentiated oral PDE4 profile could eventually pressure Otezla’s psoriasis positioning—and, if IBD studies succeed, broaden competition into another indication—but response rates in China-sponsored psoriasis trials do not establish US efficacy, tolerability, pricing, or uptake. The reported head-to-head advantage is commercially relevant only if it survives full data review and translates into durable outcomes and a tolerability edge patients and prescribers value. The sponsor’s own release and conference posters are not a substitute for peer-reviewed data; verify trial methods, subgroup consistency, and complete safety results.

Timing: near term, limited basis for repricing Amgen absent evidence of meaningful Otezla revenue sensitivity. Over 1–3 months, fuller trial data and the China NDA filing could sharpen the asset’s credibility, but do not resolve ex-China regulatory or commercial execution. Over 6–18 months, global Phase 2 IBD readouts are the key value inflection; failure would leave the competitive concern concentrated in psoriasis. The contrarian point is that efficacy leadership may be over-weighted: oral convenience and once-daily dosing matter, but established access, physician familiarity, and eventual price can dominate share. No AMGN trade is warranted on this release alone. Reassess if independent data confirm the effect and clinical development advances; thesis weakens with inconsistent results, safety/tolerability concerns, or delayed global trials.

Key Decisions for Investors

• No immediate AMGN position change: the potential Otezla threat is unapproved, early in ex-China development, and not quantified against Amgen’s consolidated results.
• Put prifemilast on a competitive watchlist; review complete poster data for endpoint definitions, baseline comparability, subgroup robustness, and the full adverse-event profile before treating the efficacy gap as durable.
• Track global Phase 2 ulcerative colitis and Crohn’s disease milestones over the next 6–18 months. Positive results could widen the competitive exposure beyond psoriasis; failed or delayed trials would materially narrow the thesis.
• Revisit an AMGN relative-value hedge only if efficacy is independently validated and credible approval/commercialization plans emerge; falsify the concern if later trials fail to reproduce the advantage or tolerability erodes it.